Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopenia

Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices

(2018) Adam Cuker   AMERICAN JOURNAL OF HEMATOLOGY

Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

(2017) Tomás José González-López et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study

(2016) Johannes Matschke et al.   ACTA HAEMATOLOGICA

High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis

(2016) Siraj Mithoowani et al.   Lancet Haematology

Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

(2015) Tomás José González-López et al.   AMERICAN JOURNAL OF HEMATOLOGY

High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial

(2015) Y. Wei et al.   BLOOD

Long-Term Effect of High-Dose Dexamethasone with or without Low-Dose Dexamethasone Maintenance in Untreated Immune Thrombocytopenia

(2014) Banhe Din et al.   ACTA HAEMATOLOGICA

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

(2014) D. Gomez-Almaguer et al.   BLOOD

The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

(2014) Matthieu Mahévas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

(2013) S. Gudbrandsdottir et al.   BLOOD

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group

(2013) F. Rodeghiero et al.   BLOOD

Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura

(2013) Jianqin Li et al.   IMMUNOLOGY LETTERS

Pathophysiology and management of primary immune thrombocytopenia

(2013) Hirokazu Kashiwagi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists

(2013) Bahareh Ghadaki et al.   TRANSFUSION

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

(2012) M. N. Saleh et al.   BLOOD

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

(2012) N. Vianelli et al.   HAEMATOLOGICA

Comparison between Pulsed High-Dose Dexamethasone and Daily Corticosteroid Therapy for Adult Primary Immune Thrombocytopenia: A Retrospective Study

(2012) Kumi Nakazaki et al.   INTERNAL MEDICINE

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

(2010) F. Zaja et al.   BLOOD

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

(2010) W. Bao et al.   BLOOD

Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients

(2010) Aamer Aleem et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura

(2008) J. Yu et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

(2008) Marta Medeot et al.   EUROPEAN JOURNAL OF HAEMATOLOGY